BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $58.50 and traded as high as $58.65. BioMarin Pharmaceutical shares last traded at $58.51, with a volume of 2,252,110 shares.
Analyst Upgrades and Downgrades
A number of equities research analysts have issued reports on the company. Barclays increased their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company an "overweight" rating in a research report on Wednesday, October 14th. Piper Sandler boosted their price objective on BioMarin Pharmaceutical from $88.00 to $90.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 1st. Royal Bank Of Canada cut their target price on shares of BioMarin Pharmaceutical from $62.00 to $60.00 and set a "sector perform" rating on the stock in a research note on Tuesday, November 3rd. Weiss Ratings cut shares of BioMarin Pharmaceutical from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, September 18th. Finally, JPMorgan Chase & Co. reduced their target price on shares of BioMarin Pharmaceutical from $87.00 to $86.00 and set an "overweight" rating on the stock in a report on Wednesday, November 4th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $87.22.
View Our Latest Stock Report on BioMarin Pharmaceutical
BioMarin Pharmaceutical Stock Performance
The firm has a 50 day moving average of $58.56 and a two-hundred day moving average of $58.50. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.44 and a quick ratio of 1.32. The stock has a market cap of $11.33 billion, a PE ratio of -585.10, a PEG ratio of 0.78 and a beta of 0.21.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.28. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.58%. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter last year, the company earned $0.12 earnings per share. The firm's revenue for the quarter was up 32.0% on a year-over-year basis. Research analysts predict that BioMarin Pharmaceutical Inc. will post 2.20 EPS for the current fiscal year.
Hedge Funds Weigh In On BioMarin Pharmaceutical
Institutional investors have recently modified their holdings of the business. Primecap Management Co. CA acquired a new stake in shares of BioMarin Pharmaceutical during the 2nd quarter worth about $811,962,000. Caisse de depot et placement du Quebec acquired a new position in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $70,749,000. Bank of New York Mellon Corp acquired a new position in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $66,107,000. Edmond DE Rothschild Holding S.A. acquired a new position in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $39,312,000. Finally, Palo Alto Investors LP purchased a new position in shares of BioMarin Pharmaceutical during the second quarter valued at approximately $39,068,500. 98.71% of the stock is owned by institutional investors and hedge funds.
BioMarin Pharmaceutical Company Profile
(
Get Free Report)
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company's marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.